Our work and that of others [47] suggests that IL-1β augments other toxins’ potencies, but our findings do not infringe on the certainty that there are other primary and secondary agents (both cellular and soluble) that contribute to the complex pathology of MS. This evidence concerns the gene IL1B and myeloid sarcoma.